T7 Peptide-Functionalized PEG-PLGA Micelles Loaded with Carmustine for Targeting Therapy of Glioma

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Glioma, a common and deadly brain tumor, presents significant treatment challenges due to its invasive nature and the restrictive blood-brain barrier (BBB).
• Carmustine (BCNU), a standard antiglioma drug, has limited clinical application due to severe complications and poor CNS penetration.
• Novel drug delivery systems are urgently needed to enhance BCNU efficacy for glioma treatment.

Purpose of the Study:

• To develop and evaluate T7 peptide-conjugated, BCNU-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles for targeted glioma therapy.
• To assess the ability of these nanoparticles to cross the BBB and accumulate in brain tumors.
• To investigate the therapeutic efficacy and safety of the targeted BCNU delivery system in vivo.

Main Methods:

• Construction of T7 peptide-conjugated, BCNU-loaded PLGA micelles using the emulsion-solvent evaporation method.
• Characterization of micelles using transmission electron microscopy (TEM) and dynamic light scattering (DLS).
• In vivo evaluation of BBB crossing, tumor targeting, therapeutic efficacy, and systemic toxicity using a BODIPY probe and tumor-bearing models.

Main Results:

• T7-modified micelles demonstrated enhanced accumulation in glioma tumors compared to unconjugated micelles.
• The targeted delivery system significantly improved therapeutic outcomes, including reduced tumor size and prolonged survival.
• The targeted group exhibited minimal body weight loss, indicating a favorable safety profile.

Conclusions:

• T7 peptide-conjugated PLGA nanoparticles represent a promising targeted delivery system for BCNU in glioma treatment.
• This approach effectively overcomes BBB limitations and enhances drug accumulation at the tumor site.
• The developed system shows significant therapeutic potential and warrants further investigation for clinical trials.